Oric Pharmaceuticals, Inc. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Oric Pharmaceuticals amended and restated its 2022 Inducement Equity Incentive Plan, authorizing a maximum of 3,350,000 shares available for issuance under the plan. The plan permits grants of nonstatutory stock options, restricted stock, RSUs, SARs, and performance awards to employees as material inducements to employment or in connection with acquisitions, subject to Nasdaq Listing Rule 5635(c). The amendment maintains standard vesting, exercise, and change-of-control provisions.
Why this rating
Routine equity plan amendment. 3.35M shares represent ~0.4% of company market cap ($862.4M). Standard administrative update; no material business change or unusual terms disclosed.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.